Abiomed's Impella(R) Technology Showcased at TCT 2013 With Over 25 Accepted Presentations in the Scientific Sessions

Abiomed Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, notes that there will be over 25 potential Impella presentations in the scientific sessions at the Cardiovascular Research Foundation's (CRF) annual Transcatheter Cardiovascular Therapeutics (TCT) 2013 scientific meeting, scheduled from October 27 -- November 1, at the Moscone Convention Center in San Francisco, CA.

On the TCT show floor, Abiomed will conduct daily booth demonstrations at Abiomed booth #1307 and hands-on simulations of the Impella platform.

For further information about the TCT scientific program and the timing of scientific presentations, please contact Aimee Genzler, Corporate Communications Manager, at agenzler@abiomed.com or 978-646-1553.

Around the web

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease.